Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

g products in any market, or at any particular time, or that such products will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisLocated in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p37spr/north_america ) ... Open System MRI Market - Growth, Trends And Forecasts ... The key players in the industry are GE ... and Toshiba Medical Systems MRI ... because of its higher sensitivity and use of non-ionizing ...
(Date:5/29/2015)... Eli Lilly and Company (NYSE: LLY ... Healthcare Conference on Tuesday, June 9, 2015. Jeffrey ... Health, will participate in a fireside chat at 2:20 ... audio webcast will be available on the "Webcasts & ... . A replay of the fireside chat will be ...
(Date:5/29/2015)... 29, 2015  The annual customer satisfaction survey of ... EMR as #1 across all specialties. Every year, ... conducts a poll of EHR users and publishes an ... Praxis EMR topped 348 other systems, ... based criteria used by Black Book. In addition to ...
Breaking Medicine Technology:North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Lilly to Participate in Goldman Sachs Global Healthcare Conference 2Praxis EMR Ranks #1 for Physician Satisfaction in Black Book's 2015 Survey of Solo and Small Practices 2
... Device to Treat Heart Attack,Victims, WALDWICK, N.J., ... competitively awarded $700,000 grant from the National,Institutes of ... investigate the,feasibility of cooling heart attack patients with ... water immersion to rapidly lower patient,temperature., The ...
... IRVINE, Calif., Oct. 20 Alsius Corporation,(Nasdaq: ... (IVTM(TM)) therapies, today announced that four scientific,posters featuring ... the,Thermogard XP(TM) was utilized will be presented this ... Meeting, taking place in Orlando., Dr. Arie ...
Cached Medicine Technology:Life Recovery Systems Receives NIH Grant to Study Expanded Use of Its ThermoSuit System 2Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 2Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 3
(Date:5/30/2015)... May 30, 2015 The results of ... asbestos has a high potential to cause mesothelioma, regardless ... story now on the Surviving Mesothelioma website. ... Occupational Medicine in Lodz, Poland found that, among the ... between 1970 and 2012, all of them happened at ...
(Date:5/30/2015)... Viejo, CA (PRWEB) May 30, 2015 ProIntro ... of unique designs and animations. Instantly add an elegant opening ... while choosing from a range of clean design layouts. ProIntro ... , ProIntro Magnify is extremely easy to use. Simply drag ... changes using the on-screen-controls and parameters in the Inspector window ...
(Date:5/30/2015)... At 73 years old, Lynn Kendall ... , which she attributes to a lifetime of being health-conscious. ... with the release of her new book titled “ Cook ... “Cook for Health and Longevity” features a collection of recipes ... organic food . It is designed to encourage a lifestyle ...
(Date:5/30/2015)... Luis Obispo, CA (PRWEB) May 30, 2015 ... Polk announced today that she is offering a free ... , The offer coincides with Disability Awareness Month, ... Happens . Industry members across the United States such ... a time to raise awareness about the possibility of ...
(Date:5/30/2015)... the Snail ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... Interactive mobile games for children have become quite popular these ... playing are doing much for their intellectual development. However, there’s ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2
... system,will be the focus of an international conference ... island nation,s healthcare system could be transformed,into an ... Affiliated,Computer Services, Inc. (ACS) will present the forum ... while showcasing practical,applications., Four recognized experts in ...
... vote soon on legislation that would cut $358 ... WASHINGTON, July 9 Seniors across Texas are,speaking ... program in,legislation being considered in the U.S. Senate. ... the Medicare Advantage program in Texas,alone and severely ...
... In battle with an epidemic that has outpaced ... strategies centered on the same antiretroviral (ARV) drugs that have ... be as effective a stronghold for preventing the virus. For ... people living with HIV/AIDS worldwide, the ARV tenofovir has particular ...
... finds more than 350 common sets of genes in patients ... activity in breast cancer cells from younger patients could explain ... a younger age. , "We haven,t had a good reason ... study author Dr. Kimberly Blackwell, director of the clinical trials ...
... China, July 9 /Xinhua-PRNewswire/ -- China Medicine,Corporation ... or " the,Company"), a leading distributor and ... Medicine (TCM), nutritional and,dietary supplements, medical devices, ... China (PRC), announced today that it released ...
... July 9 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; ... to the global life,sciences markets, today announced that ... with notice of arbitration proceedings. MDS will be,seeking ... contractual obligations,under its 2006 interim and long-term supply ...
Cached Medicine News:Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 2Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 3Health News:Texas Seniors Speak Out Against Medicare Advantage Cuts 2Health News:HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study 2Health News:HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study 3Health News:HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study 4Health News:Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 2Health News:Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 3Health News:China Medicine Releases White Paper on Developing Recombinant Aflatoxin-Detoxifizyme 2Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 2Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 3
The Vitatron Excellence + lead series are endocardial leads providing excellent handling and optimal pacing characteristics....
... Vitatron Impulse II lead series are ... to extend the longevity of the ... pacing. The high impedance of the ... small electrode surface, combined with the ...
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: